Related Experiment Video
Updated: Jul 9, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Drug interactions in inflammatory bowel disease.
Peter M Irving1, Fergus Shanahan, David S Rampton
1Department of Gastroenterology and Medicine, Box Hill Hospital and Monash University, Melbourne, Australia.
The American Journal of Gastroenterology
|December 14, 2007
Summary
Managing inflammatory bowel disease (IBD) involves multiple medications, increasing the risk of drug interactions. This review highlights key drug interactions in IBD patients to ensure safer, more effective treatment strategies.
Area of Science:
- Gastroenterology
- Clinical Pharmacology
Background:
- Inflammatory bowel disease (IBD) management frequently involves long-term combination drug therapy.
- Patients with IBD often have comorbidities requiring additional medications.
- Drug interactions can lead to serious side effects or altered therapeutic efficacy in IBD patients.
Purpose of the Study:
- To review common and significant drug-drug interactions in patients with inflammatory bowel disease (IBD).
- To identify interactions that may be therapeutically beneficial.
- To focus on interactions between drugs used specifically for IBD treatment.
Main Methods:
- Literature review of common and important drug interactions in IBD.
- Analysis of interactions relevant to IBD treatment regimens.
- Identification of interactions with potential clinical impact.
Main Results:
- Several drug combinations used in IBD management pose risks of adverse events.
- Interactions can affect the efficacy of IBD therapies.
- Some drug interactions may offer unexpected therapeutic benefits.
Conclusions:
- Awareness of drug interactions is crucial for clinicians managing IBD.
- Minimizing dangerous drug interactions improves patient safety and treatment outcomes.
- Careful consideration of all medications is necessary for optimal IBD care.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...